ClinicalTrials.gg
CompletedNCT05312918Updated Oct 16, 2026

Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)

An observational study in HIV Infections, sponsored by ANRS, Emerging Infectious Diseases. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by ANRS, Emerging Infectious Diseases · Observational

How we know

Updated Oct 16, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
487
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases — 12 open to participants now, 13 under way, none of them phase 3. HIV Infections · ANRS, Emerging Infectious Diseases.

Enrollment
12th of 22
487 · median 488
Started
2022
with 2 others
Observational
22 of 73
7 open now
Registered
59th of 73
by date

Among the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, this one is the 12th largest by enrollment of the 22 observational ones that give a count, is one of 3 that started in 2022, is one of 22 observational ones, and was the 59th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

12 of the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, or all of them as a file.
02

Study summary

Main objective The main objective of the study is to assess the virological efficacy of a Dolutegravir-based first-line ART in use under real-life conditions in national programs in resource-limited settings in patients infected with HIV-1 and initially under a NNRTI-based first-line, and determine the impact of NRTI resistance on the success of the new strategy.

Secondary objectives

  • Determine the level of virological suppression (HIV-1 RNA \<200 copies/ml) at 6, 12 and 24 months after transition from an NNRTI first-line to a DTG first-line.
  • Determine the level of virological suppression at the WHO threshold (HIV-1 RNA \<1000 copies/ml).
  • To determine the frequency of development of resistance and the profiles of mutations in patients with virological failure (HIV-1 RNA ≥200 copies/ml) and the potential impact on the 2nd line strategies combining DTG and currently recommended by the WHO.
  • To determine the impact of pre-transition resistance to NRTIs on the virological suppression under DTG first-line and on the development of resistance to integrase inhibitors.
  • Study pre-transition resistance acquired under DTG first-lines at the thresholds of 20% and 5% of the viral population, respectively using Sanger and Ultra-deep Sequencing (UDS) approaches.

Identify program factors associated with virological failure and/or the development of drug resistance.

Read the detailed description

Antiretroviral therapy (ART) has dramatically changed the pronostic of HIV/AIDS infection over the last 20 years, by reducing the mortality and morbibidity associted with the infection. This is mostly true in sub-Saharan African, the most affected region of the world. The UNAIDS 2019 report confirms this fact, and shows a significant reduction in the number of deaths related to HIV infection as access to antiretrovirals (ARV) increases. However, in the absence of cure by current treatments, the management and treatment of the infection should still be considered for life. This makes this management complex and challenging. Indeed, the risk of failure to treatment is real, this risk is accompanied by that of developing resistance to treatment, which should lead to a change in treatment. The limited number of molecules therefore requires the development of strategies that must be effective in maintaining virological suppression for as long as possible and should also limit the emergence and circulation of resistant viruses. To address these priorities, the World Health Organization (WHO) recommends since 2016, the introduction of a first-line ART more efficient and more robust, combining molecules with a high genetic barrier to resistance. In its latest 2019 recommendations for resource-limited countries, WHO recommends a first-line ART comprising two nucleoside reverse transcriptase inhibitors (NRTIs) and one integrase inhibitor (INI), preferably tenofovir (TDF)+Lamivudine (3TC )/emtricitabine (FTC)+dolutegravir (DTG). This new strategy is expected in the context of sub-Saharan Africa, where the increase of pre-treatment and acquired HIV drug resistance has been worrying for several years, but raises a certain number of uncertainties. Indeed, available and published data on the effectiveness of DTG are mainly from studies conducted in Northern countries, very few clinical trials have evaluated or are underway to evaluate the strategy in Southern countries and virtually no evaluation of the effectiveness of this approach in the context of real life in the South has been conducted to date. In addition, few or no recommendations have been made to accompany this transition to a new DTG-based first-line in the South. This is of greater concern for patients who are currently under non-NRTI-based first-line , and who will be switched to a new DTG-based first-line. This population will certainly include very variable virological profiles, ranging from patients in virological suppression, to patients who are not virologically suppressed, with potential accumulation of resistance mutations. In the absence of clear and funded recommendations for the organization of these transitions, the risk of this transition producing results below expectations is real and significant. In addition, the reality of the management of HIV infection in the South regularly faces significant challenges associated with limited financial and human resources. This often makes it difficult to apply decisions made even at the national level. For illustration, despite the unanimity around the use of viral load for monitoring people on ART, access to and the availability of this test in daily practice remains challenging in many countries. It is therefore essential to evaluate the virological response in people who will be switched from the current first-line, to the new first-line, in real life conditions, in the South. This study, developed and considered as a priority by the AC43 working group "Medical Virology" of the ANRS, aims to evaluate this new strategy in real life context in three countries of sub-Saharan Africa, Côte d'Ivoire, Mali and Togo. The main objective is to assess the virological efficacy of the DTG-based first-line in real life conditions, for patients initially receiving an NNRTI-based first-line, followed-up in the national programs and determine the impact of baseline NRTI-drug resistance on the success of the new strategy. All these three countries have adopted the new WHO recommendations and the deployment of the DTG-based first-line is being initiated. It is therefore essential that this research be conducted along side with this ongoing transition, so that the results will help developping adequate recommendations that will allow programs in the South to better organise the transition, to improve the therapeutic and virological monitoring of patients, to prevent early failures, and the emergence and rapid circulation of drug resistance.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV Infections
  • Dolutegravir
  • HIV drug resistance
  • Real Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

HIV-1 infected individuals who are transitioning from an NNRTI-based first-line to a Dolutegravir-based first-line treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or over.
  • Infected with -1.
  • On an NNRTI-based for at least 6 months.
  • Initiating a new 1st line ART based on DTG according to national recommendations.
  • Agree to participate in the study and provide free, written and .

Exclusion criteria

Exclusion Criteria:

  • Infection with -2 or HIV1+2.
  • Ongoing participation in another virological study on HIV infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
487 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Proportion virological success

    Proportion of patients with virological success at Week 48 (Month 12), defined by a VL \<200 copies/ml.

    Time frame: 48 weeks

Secondary outcomes

  1. Virological suppression at W24 (VL< 200 copies/ml)

    Proportion of patients with virological suppression at W24 (VL\< 200 copies/ml).

    Time frame: 24 weeks

  2. Virological suppression at W96 (VL< 200 copies/ml)

    Proportion of patients with virological suppression at W96 (VL\< 200 copies/ml).

    Time frame: 96 weeks

  3. Virological suppression at VL thresholds of 200 copies/ml, considering the first point of viral load and the control viral load if the first point of viral load was >200 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 200 copies/ml, considering the first point of viral load at W24 and the control viral load at W36 if the first point of viral load was \>200 copies/ml.

    Time frame: 36 weeks

  4. Virological suppression at VL thresholds of 200 copies/ml, considering the first point of viral load and the control viral load if the first point of viral load was >200 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 200 copies/ml, considering the first point of viral load at W48, and the control viral load at W60 if the first point of viral load was \>200 copies/ml.

    Time frame: 60 weeks

  5. Virological suppression at VL thresholds of 200 copies/ml, considering the first point of viral load and the control viral load if the first point of viral load was >200 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 200 copies/ml, considering the first point of viral load at W96, and the control viral load at W108 if the first point of viral load was \>200 copies/ml.

    Time frame: 108 weeks

  6. Virological suppression at the WHO threshold (< 1000 copies/ml).

    Proportion of patients with virological suppression at the WHO threshold at W24 (\< 1000 copies/ml).

    Time frame: 24 weeks

  7. Virological suppression at the WHO threshold (< 1000 copies/ml).

    Proportion of patients with virological suppression at the WHO threshold at W48 (\< 1000 copies/ml).

    Time frame: 48 weeks

  8. Virological suppression at the WHO threshold (< 1000 copies/ml).

    Proportion of patients with virological suppression at the WHO threshold at W96 (\< 1000 copies/ml).

    Time frame: 96 weeks

  9. Virological suppression at VL thresholds of 1000 copies/ml, considering the first point of viral load, and the control viral load if the first point of viral load was >1000 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 1000 copies/ml, considering the first point of viral load at W24, and the control viral load at W36 if the first point of viral load was \>1000 copies/ml.

    Time frame: 36 weeks

  10. Virological suppression at VL thresholds of 1000 copies/ml, considering the first point of viral load, and the control viral load if the first point of viral load was >1000 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 1000 copies/ml, considering the first point of viral load at W48, and the control viral load at W60 if the first point of viral load was \>1000 copies/ml.

    Time frame: 60 weeks

  11. Virological suppression at VL thresholds of 1000 copies/ml, considering the first point of viral load, and the control viral load if the first point of viral load was >1000 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 1000 copies/ml, considering the first point of viral load at W96, and the control viral load at W108 if the first point of viral load was \>1000 copies/ml.

    Time frame: 108 weeks

  12. Virological suppression at the optimal threshold (<50 copies/ml)

    Proportion of patients with virological suppression at the optimal threshold at W24 (\<50 copies/ml)

    Time frame: 24 weeks

  13. Virological suppression at the optimal threshold (<50 copies/ml)

    Proportion of patients with virological suppression at the optimal threshold at W48 (\<50 copies/ml)

    Time frame: 48 weeks

  14. Virological suppression at the optimal threshold (<50 copies/ml)

    Proportion of patients with virological suppression at the optimal threshold at W96 (\<50 copies/ml)

    Time frame: 96 weeks

  15. Virological suppression at VL thresholds of 50 copies/ml, considering the first point of viral load, and the control viral load if the first point of viral load was >50 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 50 copies/ml, considering the first point of viral load at W24, and the control viral load at W36 if the first point of viral load was \>50 copies/ml.

    Time frame: 36 weeks

  16. Virological suppression at VL thresholds of 50 copies/ml, considering the first point of viral load, and the control viral load if the first point of viral load was >50 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 50 copies/ml, considering the first point of viral load at W48, and the control viral load at W60 if the first point of viral load was \>50 copies/ml.

    Time frame: 60 weeks

  17. Virological suppression at VL thresholds of 50 copies/ml, considering the first point of viral load, and the control viral load if the first point of viral load was >50 copies/ml.

    Proportion of patients with virological suppression at VL thresholds of 50 copies/ml, considering the first point of viral load at W96, and the control viral load at W108 if the first point of viral load was \>50 copies/ml.

    Time frame: 108 weeks

  18. Proportion of patients with virological suppression at VL thresholds of 50, 200 copies/ml and 1000 copies/ml, depending on the viral load at the time of switch

    Proportion of patients with virological suppression at VL thresholds of 50, 200 copies/ml and 1000 copies/ml, at W24, depending on the viral load at the time of switch according to 3 groups (VL of D0 \<200 copies/ml, between 200 and 1000 copies/ml, and ≥1000 copies/ml)

    Time frame: 24 weeks

  19. Proportion of patients with virological suppression at VL thresholds of 50, 200 copies/ml and 1000 copies/ml, depending on the viral load at the time of switch

    Proportion of patients with virological suppression at VL thresholds of 50, 200 copies/ml and 1000 copies/ml, at W48, depending on the viral load at the time of switch according to 3 groups (VL of D0 \<200 copies/ml, between 200 and 1000 copies/ml, and ≥1000 copies/ml)

    Time frame: 48 weeks

  20. Proportion of patients with virological suppression at VL thresholds of 50, 200 copies/ml and 1000 copies/ml, depending on the viral load at the time of switch

    Proportion of patients with virological suppression at VL thresholds of 50, 200 copies/ml and 1000 copies/ml, at W96, depending on the viral load at the time of switch according to 3 groups (VL of D0 \<200 copies/ml, between 200 and 1000 copies/ml, and ≥1000 copies/ml)

    Time frame: 96 weeks

  21. Frequency of drug resistance

    Frequency of resistance mutations acquired at confirmed virological failure, at VL thresholds of 200 copies/ml and 1000 copies/ml.

    Time frame: 24 weeks

  22. Profiles of resistance mutations

    Profiles of resistance mutations acquired at confirmed virological failure, at VL thresholds of 200 copies/ml and 1000 copies/ml.

    Time frame: 24 weeks

  23. Frequency of drug resistance

    Frequency of resistance mutations acquired at confirmed virological failure, at VL thresholds of 200 copies/ml and 1000 copies/ml.

    Time frame: 48 weeks

  24. Profiles of resistance mutations

    Profiles of resistance mutations acquired at confirmed virological failure, at VL thresholds of 200 copies/ml and 1000 copies/ml.

    Time frame: 48 weeks

  25. Frequency of drug resistance

    Frequency of resistance mutations acquired at confirmed virological failure, at VL thresholds of 200 copies/ml and 1000 copies/ml.

    Time frame: 96 weeks

  26. Profiles of resistance mutations

    Profiles of resistance mutations acquired at confirmed virological failure, at VL thresholds of 200 copies/ml and 1000 copies/ml.

    Time frame: 96 weeks

  27. GSS (Genotypic susceptibility score)

    Proportion of patients with a GSS ≤1 at W24

    Time frame: 24 weeks

  28. GSS (Genotypic susceptibility score)

    Proportion of patients with a GSS ≤1 at W48

    Time frame: 48 weeks

  29. GSS (Genotypic susceptibility score)

    Proportion of patients with a GSS ≤1 at W96.

    Time frame: 96 weeks

  30. Frequency of pre-transition resistance mutations to NRTIs

    Frequency of pre-transition resistance mutations to NRTIs

    Time frame: At baseline, before DTG initiation

  31. Proportion of HIV minority variants

    Proportion of minority variants (5% threshold) in patients with resistance mutations to NRTIs and/or DTG in the event of virological failure.

    Time frame: Up to 108 weeks.

07

Study locations

3 sites
  • CIRBA
    Abidjan, Côte d’Ivoire
  • SEREFO
    Bamako, Mali
  • Biolim/Fss/Ul
    Lomé, Togo
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Sep 2023, 12 months.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 12 months is below that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start May 2022 → Sep 2022, primary completion Mar 2023 → Sep 2023 and completion Oct 2024 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Apr 6, 2022
StartActual
Sep 9, 2022was May 2022
Primary completionActual
Sep 9, 2023was Mar 2023
CompletionActual
Nov 25, 2025was Oct 2024
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 16, 2026
Start date
May 2022→Sep 9, 2022 (actual)
Oct 16, 2026
Primary completion
Mar 2023→Sep 9, 2023 (actual)
Oct 16, 2026
Study completion
Oct 2024→Nov 25, 2025 (actual)
Oct 16, 2026
Enrollment
603 (estimated)→487 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Status unknown→Completed
    Start date May 2022→Sep 9, 2022 (now actual)
    Primary completion Mar 2023→Sep 9, 2023 (now actual)
    Study completion Oct 2024→Nov 25, 2025 (now actual)
    Enrollment 603 (estimated)→487 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05312918
Collaborators
CIRBA, Abidjan, Ivory Coast, SEREFO, Bamako, Mali, BIOLIM/FSS/UL, Lomé, Togo
Responsible party
Sponsor
First posted
Apr 6, 2022
Start date
Sep 9, 2022
Primary completion
Sep 9, 2023
Completion
Nov 25, 2025
Last update
Oct 16, 2026

Study contacts

Avelin AGHOKENG
study director · IRD 224 - CNRS 5290 - UM1-UM2
Anoumou Claver DAGNRA
study director · BIOLIM - FSS - UL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion